ZOLL Medical Corporation, an Asahi Kasei Group company that manufactures medical devices and related software solutions, has acquired Tel Aviv, Israel-based Kyma Medical Technologies, which develops technologies to measure early signs of congestive heart failure.

Currently, Kyma is working on a remote patient monitoring system for fluid management in a variety of patients including those suffering from heart failure. The µ-Cor System uses radio frequency-based technology to monitor the level of fluid in the lungs, and can also collect data on heart rate, respiration rate, activity, and posture to determine patient-specific vital signs trends. Once a potential deterioration in the patient’s condition is identified, a notification is sent to the patient’s medical team.

ZOLL plans to maintain Kyma’s facilities and workforce in Israel and California as a part of ZOLL’s LifeVest division.“The acquisition of Kyma Medical will allow ZOLL to broaden its product offerings with additional technologies designed to improve outcomes for heart failure patients with fluid management problems, with the goal of reducing hospitalizations,” said Jason T. Whiting, President of ZOLL LifeVest. “With the acquisition, Kyma’s technology will be able to better reach global markets through ZOLL’s existing network. Additionally, we expect to leverage Kyma’s strong R&D capabilities as well as the broader research talent available in Israel.”

In January 2015, Kyma announced that it had received CE Mark approval for the µ-Cor System for monitoring thoracic fluid content, ECG, heart rate, respiration rate, activity, and posture.

ZOLL plans to maintain Kyma’s facilities and workforce in Israel and California as a part of ZOLL’s LifeVest division.